4.2 Article

Beneficial effect of anti-interleukin-4 antibody when administered in a murine model of tuberculosis infection

Journal

TUBERCULOSIS
Volume 88, Issue 3, Pages 197-202

Publisher

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.tube.2007.11.005

Keywords

murine tuberculosis; immunotherapy; anti-IL-4; anti-IL-13

Ask authors/readers for more resources

There remains much controversy surrounding the role of Th2 cytokines, such as interleukin-4 (IL-4), in tuberculosis infection. Here we demonstrate that anti-IL-4 antibody, administered as a pulse during the early or late stages of murine infection, can provide significant reductions in the bacterial, burden. The fact that substantial benefit can be achieved when treatment is administered during established infection strengthens the view that clinical interventions aimed at suppressing the IL-4 component of the host immune response seen in tuberculosis patients may be beneficial. (C) 2007 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Infectious Diseases

Differential T cell responses against DosR-associated antigen Rv2028c in BCG-vaccinated populations with tuberculosis infection

Hui-Min Zhao, Rui Du, Chun-Ling Li, Ping Ji, Hai-cong Li, Kang Wu, Zhidong Hu, Shui-Hua Lu, Douglas B. Lowrie, Xiao-Yong Fan

JOURNAL OF INFECTION (2019)

Letter Infectious Diseases

The predictive values of the tuberculin skin test and interferon-γ release assays for active tuberculosis development

Zhidong Hu, Shui-Hua Lu, Douglas B. Lowrie, Xiao-Yong Fan

LANCET INFECTIOUS DISEASES (2019)

Article Immunology

British Society for Immunology/United Kingdom Primary Immunodeficiency Network consensus statement on managing non-infectious complications of common variable immunodeficiency disorders

C. Bethune, W. Egner, T. Garcez, A. Huissoon, S. Jolles, Y. Karim, R. Jain, S. Savic, K. Kelley, D. Grosse-Kreul, S. Grigoriadou

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2019)

Article Immunology

European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline: Deficiencies, Diagnosis, and Management

Nicholas Brodszki, Ashley Frazer-Abel, Anete S. Grumach, Michael Kirschfink, Jiri Litzman, Elena Perez, Mikko R. J. Seppanen, Kathleen E. Sullivan, Stephen Jolles

JOURNAL OF CLINICAL IMMUNOLOGY (2020)

Letter Critical Care Medicine

Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19

Wioleta M. Zelek, Jade Cole, Mark J. Ponsford, Richard A. Harrison, Ben E. Schroeder, Nicholas Webb, Stephen Jolles, Christopher Fegan, Matt Morgan, Matt P. Wise, B. Paul Morgan

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)

Article Allergy

Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations

Hans-Hartmut Peter, Hans D. Ochs, Charlotte Cunningham-Rundles, Donald C. Vinh, Peter Kiessling, Bernhard Greve, Stephen Jolles

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

Letter Immunology

COVID-19 Vaccine Uptake and Efficacy in a National Immunodeficiency Cohort

Mark J. Ponsford, Kimberly Evans, Emily M. Carne, Stephen Jolles

JOURNAL OF CLINICAL IMMUNOLOGY (2022)

Letter Immunology

Persistent COVID-19 Infection in Wiskott-Aldrich Syndrome Cleared Following Therapeutic Vaccination: a Case Report

Rachel E. Bradley, Mark J. Ponsford, Martin J. Scurr, Andrew Godkin, Stephen Jolles

JOURNAL OF CLINICAL IMMUNOLOGY (2022)

Article Oncology

Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies

Stephen Jolles, B. Douglas Smith, Donald C. Vinh, Rajiv Mallick, Gabriela Espinoza, Mitchell DeKoven, Victoria Divino

Summary: Real-world data are lacking to identify which patients with secondary immunodeficiency may benefit most from anti-infective interventions. The retrospective analysis used baseline characteristics to assess risk of severe infections post-SID diagnosis in patients with hematological malignancies. Evaluation of risk factors such as hospitalizations, infections, or antibiotic use pre-SID diagnosis could inform clinical decisions regarding prophylactic anti-infective treatment.

LEUKEMIA & LYMPHOMA (2022)

Article Virology

A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination

Zhidong Hu, Jian-Ping Chen, Jin-Chuan Xu, Zhen-Yan Chen, Rong Qu, Ling Zhang, Wenrong Yao, Juan Wu, Heng Yang, Douglas B. Lowrie, Yong Liu, Xiao-Yong Fan

Summary: This study investigated the adjuvant effect of AS01 in a COVID-19 vaccine. The results showed that the adjuvanted vaccine induced strong antibody responses, and two doses of the vaccine were as effective as three doses.

VIROLOGY (2022)

Article Oncology

Mycobacterium tuberculosis Rv3628 is an effective adjuvant via activation of dendritic cells for cancer immunotherapy

Juan Wu, Heng Yang, Jin-chuan Xu, Zhidong Hu, Wen-fei Gu, Zhen-yan Chen, Jing-xian Xia, Douglas B. Lowrie, Shui-Hua Lu, Xiao-Yong Fan

Summary: The study demonstrated that Rv3628 could effectively enhance DC activation and antigen presentation, leading to improved anti-tumor immune responses in cancer patients.

MOLECULAR THERAPY-ONCOLYTICS (2021)

Review Psychology, Multidisciplinary

Fatigue Symptoms Associated With COVID-19 in Convalescent or Recovered COVID-19 Patients; a Systematic Review and Meta-Analysis

Sanjay Rao, Tarek Benzouak, Sasha Gunpat, Rachel J. Burns, Tayyeb A. Tahir, Stephen Jolles, Steve Kisely

Summary: This study systematically evaluated the prevalence of fatigue after recovery from COVID-19. The results showed that post-COVID-19 patients reported higher levels of fatigue compared to healthy controls. Over 50% of inpatients and 10% of community patients reported fatigue during the first month post-recovery. Female patients had a higher self-report of fatigue, and patients recruited through social media had the highest levels of fatigue.

ANNALS OF BEHAVIORAL MEDICINE (2022)

Article Biotechnology & Applied Microbiology

Maternal SARS-CoV-2 sero-surveillance using newborn dried blood spot (DBS) screening specimens highlights extent of low vaccine uptake in pregnant women

Stuart J. Moat, Sharon Hillier, Sikha de Souza, Malorie Perry, Simon Cottrell, Alex Lench, Heather Payne, Stephen Jolles

Summary: SARS-CoV-2 vaccine uptake in pregnant women is low and lags behind the general population, leading to increased hospital admissions and poor maternal and fetal outcomes. Our study demonstrates the importance of analyzing newborn screening samples to monitor the serostatus of pregnant women and assess the impact of interventions.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

Review Immunology

Phenotypic Variability in PRKCD: a Review of the Literature

Lucy Jefferson, Athimalaipet Vaidyanathan Ramanan, Stephen Jolles, Jolanta Bernatoniene, Anne-Laure Mathieu, Alexandre Belot, Marion Ruth Roderick

Summary: This article reviews the current data on the pathophysiology, clinical presentation, investigation and management of PKC delta deficiency. Twenty cases have been described in the literature with significant heterogeneity.

JOURNAL OF CLINICAL IMMUNOLOGY (2023)

No Data Available